BACKGROUND: Recent studies have showed podoplanin expression in several tumors, which has been associated with lymph node metastasis and poor prognosis. Podoplanin expression in cancer-associated fibroblasts also correlates with tumor progression. However, the association of podoplanin expression with melanomas remains unclear. METHODS: To clarify the prognostic significance of podoplanin in melanoma, podoplanin expression in tumor cells and cancer-associated fibroblasts was examined by immunohistochemistry in tissue samples collected from 55 melanoma patients. RESULTS: Podoplanin expression in tumor cells was identified in 38 patients (69.1%) but did not show correlation with characteristics of tumor progression such as tumor thickness (p = 0.52) and sentinel lymph node (SLN) metastasis (p = 0.79). Podoplanin expression in cancer-associated fibroblasts was observed in 25 patients (45.5%), 11 of whom (44.0%) had SLN metastasis. In contrast, only 4 of 30 patients (13.3%) with podoplanin-negative cancer-associated fibroblasts exhibited SLN metastasis. Podoplanin-positive cancer-associated fibroblasts were associated with increased tumor thickness and SLN metastasis. Furthermore, patients with podoplanin-positive cancer-associated fibroblasts had poorer survival than those with podoplanin-negative cancer-associated fibroblasts (p = 0.0148). CONCLUSION: The presence of podoplanin expression in cancer-associated fibroblasts correlates with aggressive behavior in melanoma and might therefore serve as a useful prognostic factor for patients with melanoma.
BACKGROUND: Recent studies have showed podoplanin expression in several tumors, which has been associated with lymph node metastasis and poor prognosis. Podoplanin expression in cancer-associated fibroblasts also correlates with tumor progression. However, the association of podoplanin expression with melanomas remains unclear. METHODS: To clarify the prognostic significance of podoplanin in melanoma, podoplanin expression in tumor cells and cancer-associated fibroblasts was examined by immunohistochemistry in tissue samples collected from 55 melanomapatients. RESULTS:Podoplanin expression in tumor cells was identified in 38 patients (69.1%) but did not show correlation with characteristics of tumor progression such as tumor thickness (p = 0.52) and sentinel lymph node (SLN) metastasis (p = 0.79). Podoplanin expression in cancer-associated fibroblasts was observed in 25 patients (45.5%), 11 of whom (44.0%) had SLN metastasis. In contrast, only 4 of 30 patients (13.3%) with podoplanin-negative cancer-associated fibroblasts exhibited SLN metastasis. Podoplanin-positive cancer-associated fibroblasts were associated with increased tumor thickness and SLN metastasis. Furthermore, patients with podoplanin-positive cancer-associated fibroblasts had poorer survival than those with podoplanin-negative cancer-associated fibroblasts (p = 0.0148). CONCLUSION: The presence of podoplanin expression in cancer-associated fibroblasts correlates with aggressive behavior in melanoma and might therefore serve as a useful prognostic factor for patients with melanoma.
Authors: Harini Krishnan; Edward P Retzbach; Maria I Ramirez; Tong Liu; Hong Li; W Todd Miller; Gary S Goldberg Journal: Exp Cell Res Date: 2015-05-07 Impact factor: 3.905
Authors: Jhon A Ochoa-Alvarez; Harini Krishnan; John G Pastorino; Evan Nevel; David Kephart; Joseph J Lee; Edward P Retzbach; Yongquan Shen; Mahnaz Fatahzadeh; Soly Baredes; Evelyne Kalyoussef; Masaru Honma; Martin E Adelson; Mika K Kaneko; Yukinari Kato; Mary Ann Young; Lisa Deluca-Rapone; Alan J Shienbaum; Kingsley Yin; Lasse D Jensen; Gary S Goldberg Journal: Oncotarget Date: 2015-04-20
Authors: Jaroslaw Suchanski; Anna Tejchman; Maciej Zacharski; Aleksandra Piotrowska; Jedrzej Grzegrzolka; Grzegorz Chodaczek; Katarzyna Nowinska; Janusz Rys; Piotr Dziegiel; Claudine Kieda; Maciej Ugorski Journal: PLoS One Date: 2017-09-22 Impact factor: 3.240